Clinical Trials Logo
  1. Home
  2. Primary Open Angle Glaucoma
  3. NCT03673644

Impact of Glaucoma and Visual Field Loss on Life Space

Primary Open-angle Glaucoma Clinical Trial

Official title:
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

Clinical Trial Summary

Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.

Clinical Trial Description

Aim 1: To examine the extent of life space in older adults with POAG using the Life Space Questionnaire and to examine whether life space in persons with POAG is associated with the magnitude of visual field impairment. Aim 2: To examine difficulties seeing under dim illumination and at night in older adults with POAG using the Low Luminance Questionnaire and to examine whether greater difficulty in seeing under dim illumination and at night is related to the magnitude of visual field loss. Aim 3: To examine the relationship in older adults with POAG between visual problems seeing under dim illumination and at night (Low Luminance Questionnaire) and their life space (Life Space Questionnaire). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03673644
Study type Observational
Source University of Alabama at Birmingham
Contact
Status Active, not recruiting
Phase
Start date October 9, 2018
Completion date May 30, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01841437 - Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry N/A
Completed NCT02077231 - Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients N/A
Completed NCT01410188 - Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension Phase 1/Phase 2
Recruiting NCT05557058 - GORE Glaucoma Drainage Implant Clinical Study N/A
Not yet recruiting NCT03924544 - Decorin in Sub Scleral Trabeculectomy Phase 1
Completed NCT03365778 - Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment N/A
Completed NCT01915940 - Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Phase 2
Completed NCT03889652 - Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
Terminated NCT03273907 - Post Approval Study of the CyPass System N/A
Recruiting NCT03193333 - PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) Phase 3
Recruiting NCT03921931 - Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study N/A
Not yet recruiting NCT04609345 - Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
Recruiting NCT05264818 - Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
Completed NCT04333433 - PRESERFLO® MicroShunt Extension Study
Enrolling by invitation NCT02144103 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Phase 1/Phase 2
Completed NCT01281020 - Adherence With Fixed Versus Unfixed Glaucoma Therapy
Recruiting NCT04891588 - Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD N/A
Completed NCT03145129 - PAIR Study-PAP And IOP Relationship: Study 2
Completed NCT03104621 - Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Phase 4
Completed NCT01528111 - Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Phase 1/Phase 2